Ampio Pharmaceuticals, INC

Ampio Pharmaceuticals has reached a proposed settlement in multiple shareholder derivative actions and demands, and is planning to dissolve the company.

Ampio Pharmaceuticals has announced its decision to voluntarily delist from the NYSE American and deregister its common stock with the SEC, citing high costs and non-compliance with listing requirements.

Ampio Pharmaceuticals has terminated its at-the-market equity distribution agreement with H.C. Wainwright & Co., LLC, effective March 6, 2024.

Ampio Pharmaceuticals' recent preclinical studies for its OA-201 osteoarthritis treatment failed to demonstrate the pain reduction benefits seen in earlier trials, jeopardizing its IND submission and future development.

Ampio Pharmaceuticals has filed a prospectus supplement to potentially sell up to $1.3 million of its common stock through an existing at-the-market offering agreement.

Ampio Pharmaceuticals has reached settlements in principle for a securities fraud class action and consolidated derivative actions, with costs expected to be covered by its D&O insurance.

Ampio Pharmaceuticals will voluntarily delist from the NYSE American and wind down operations after disappointing non-clinical trial results for its lead drug candidate, OA-201.